检索结果-南通市图书馆

Expression of T cell factor-4 in non-small-cell lung cancer

中华医学杂志(英文版) 2005年第2期000卷 50-54页

作者： li chun yan, wang yan, cui ze shi and wang en hua department of medical devices and supplies, center of medical laboratory technology, china medical university, shenyang 110001, china department of pathology,china medical university, shenyang 110001, china department of medical devices and supplies Center of Medical Laboratory Technology China Medical University Shenyang 110001 China department of pathology China Medical University Shenyang 110001 China

Background T cell factor 4 (TCF 4) plays an important role in development and carcinogenesis Recently, the role of TCF 4 has been described in colon cancer and other cancers However, whether TCF 4 plays a similar role in lung cancer is unknown To answer this question, we studied the expression of TCF 4 protein and mRNA in nonsmallcell lung cancer (NSCLC) and the relation of TCF 4 expression pattern to histological type and cell differentiation Methods Tissue samples from sixty cases of pathologically diagnosed NSCLC and eight normal tissue samples were obtained between September 2001 and March 2003 Immunohistochemistry was used to investigate the distribution of TCF 4 protein The staining patterns of the tumors were divided into 4 categories: nuclear staining alone or nuclear staining greater than cytoplasmic staining; cytoplasmic staining or cytoplasmic staining greater than nuclear staining; equal nuclear and cytoplasmic staining; no nuclear staining or cytoplasmic staining The integrated optical density (OD) values of all sections were analyzed by UIC MetaMorph image analysis software The expression of TCF 4 mRNA was detected by onestep reverse transcriptionpolymerase chain reaction (RTPCR) The integrated density values of the PCR products were analyzed semiquantitatively Results Immunohistochemistry showed that there was no expression of TCF 4 in normal tissue However, TCF 4 was expressed in 86.7% (52/60) of NSCLC samples, mainly in the nuclei of tumor cells Furthermore, there was a significant difference in TCF 4 localization patterns between squamous cell carcinomas and adenocarcinomas (Pentiation than in well differentiated tumors (5163±667 vs 4613±1231, P<001) There was no TCF 4 mRNA expression in normal tissue However, 63.9% (23/36) of carcinoma samples expressed TCF 4 mRNA TCF 4 mRNA expression w

关键词： T cell factor 4 · non small cell lung cancer · immunohistochemistry · reverse transcription polymerase chain reaction

来源：

同方期刊数据库评论

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

A five-compartment model of age-specific transmissibility of SARS-CoV-2

引用

Infectious Diseases of Poverty 2020年第4期9卷 35-49页

作者： ze-Yu Zhao Yuan-Zhao Zhu Jing-Wen Xu shi-Xiong Hu Qing-Qing Hu Zhao Lei Jia Rui Xing-chun liu Yao wang Meng yang li Luo Shan-Shan Yu Jia li Ruo-Yun liu Fang Xie Ying-Ying Su Yi-Chen Chiang Ben-hua Zhao Jing-An cui ling Yin yan-hua Su Qing-Long Zhao li-Dong Gao Tian-Mu Chen State Key laboratory of Molecular Vaccinology and Molecular Diagnostics School of Public HealthXiamen University4221-117 South Xiang'an RoadXiang'an DistrictXiamen City 361102Fujian ProvincePeople's Republic of China Hunan Provincial center for Disease Control and Prevention 405 Furong Middle Road Section OneKaifu DistrictChangsha City 410001Hunan ProvincePeople's Republic of China Division of Public Health School of MedicineUniversity of Utah201 Presidents CircleSalt Lake CityUT 84112USA department of Mathematics School of ScienceBeijing University of Civil Engineering and ArchitectureBeijingPeople's Republic of China Shenzhen Institutes of Advanced technology Chinese Academy of SciencesShenzhenGuangdong ProvincePeople's Republic of China Jilin Provincial center for Disease Control and Prevention 3145 Jingyang Big RoadLvyuan DistrictChangchun 130062Jilin ProvincePeople's Republic of China

Background:The novel coronavirus,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2,also called 2019-nCoV)causes different morbidity risks to individuals in different age *** study attempts to quantify the age-specific transmissibility using a mathematical ***:An epidemiological model with five compartments(susceptible-exposed-symptomatic-asymptomatic-recovered/removed[SEIAR])was developed based on observed transmission *** disease 2019(COVID-19)cases were divided into four age groups:group 1,those≤14years old;group 2,those 15 to 44years old;group 3,those 45 to 64years old;and group 4,those≥65 years *** model was initially based on cases(including imported cases and secondary cases)collected in Hunan Province from January 5 to February 19,*** dataset,from Jilin Province,was used to test the ***:The age-specific SEIAR model fitted the data well in each age group(Plity was from age group 4 to 3(median:β43=7.71×10-9;SAR43=3.86×10-8),followed by group 3 to 4(median:β34=3.07×10-9;SAR34=1.53×10-8),group 2 to 2(median:β22=1.24×10-9;SAR22=6.21×10-9),and group 3 to 1(median:β31=4.10×10-10;SAR31=2.08×10-9).The lowest transmissibility was from age group 3 to 3(median:β33=1.64×10-19;SAR33=8.19×10-19),followed by group 4 to 4(median:β44=3.66×10-17;SAR44=1.83×10-16),group 3 to 2(median:β32=1.21×10-16;SAR32=6.06×10-16),and group 1 to 4(median:β14=7.20×10-14;SAR14=3.60×10-13).In Jilin Province,the highest transmissibility occurred from age group 4 to 4(median:β43=4.27×10-8;SAR43=2.13×10-7),followed by group 3 to 4(median:β34=1.81×10-8;SAR34=9.03×10-8).Conclusions:SARS-CoV-2 exhibits high transmissibility between middle-aged(45 to 64 years old)and elderly(≥65 years old)***(≤14 years old)have very low susceptibility to *** study will improve our understanding of the transmission feature of SARS-CoV-2 in different age groups and suggest the most pre

关键词： Transmissibility SARS-CoV-2 COVID-19 Compartmental model Age-specific dynamics

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

对“系列方药”同步转化的创新中药研发注册路径的思考

引用

中国中药杂志 2022年第4期47卷 1120-1125页

作者：艾彦伶唐健元周刚张磊瞿礼萍黄诗尧杨忠奇元唯安周跃华王停赵军宁孙晓波肖小河杨子锋刘清泉朱明军冷向阳谢春光柴嵩岩成都中医药大学附属医院四川成都610075 国家药品监督管理局药品审评中心北京100022 上海中医药大学上海201203 成都中医药大学西南特色中药资源国家重点实验室四川成都610037 广州中医药大学第一附属医院广东广州510405 上海中医药大学附属曙光医院上海201203 北京中医药大学北京100029 四川省中医药科学院国家中医药管理局中药质量生物评价重点研究室四川成都610041 中国医学科学院中国协和医科大学药用植物研究所北京100094 解放军总医院第五医学中心全军中医药研究所北京100039 广州医科大学呼吸疾病国家重点实验室广东广州510180 首都医科大学附属北京中医医院北京100010 河南中医药大学第一附属医院河南郑州450099 长春中医药大学吉林长春130117

自我国实施药品注册管理以来,中药注册分类在满足公众健康需求、指导中医药科研成果转化及传承创新上发挥了重要作用。三十余年间,中药新药创制均基于"一方一药"的注册转化模式。该模式借鉴了现代药品的研发注册制度,虽然贴近中医临床中... 详细信息

自我国实施药品注册管理以来,中药注册分类在满足公众健康需求、指导中医药科研成果转化及传承创新上发挥了重要作用。三十余年间,中药新药创制均基于"一方一药"的注册转化模式。该模式借鉴了现代药品的研发注册制度,虽然贴近中医临床中的"守方守法"用药,但难以体现中医辨证求因的序贯治疗思想和多措并举的综合治疗手段。2017年,中共中央办公厅、国务院办公厅《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》指出要"建立完善符合中药特点的注册管理制度和技术评价体系,处理好保持中药传统优势与现代药品研发要求的关系"。因此,现阶段中药研发的技术要求和注册制度需要在遵循中医药发展规律、符合中医药理论特点基础上进一步解放思路,更多地基于临床思维去思考设计。该文结合我国中药注册监管情形和现代药物研发模式转变,分析当前"一方一药"研发注册模式的局限和不足,并尝试提出一种更加切合中医临证思维、还原中医临床实景的"系列方药"同步转化的研发注册新模式,希望有助于中医药产业的传承创新和高质量发展。

关键词：中药新药研发注册同步转化系列方药

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：